Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 23:13:4979-4986.
doi: 10.2147/CMAR.S311326. eCollection 2021.

Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management

Angel Yordanov  1 , Stoyan Kostov  2 , Stanislav Slavchev  2 , Strahil Strashilov  3 , Assia Konsoulova  4 , Jean Calleja-Agius  5 , Riccardo Di Fiore  5   6 , Sherif Suleiman  5 , Paul Kubelac  7   8 , Catalin Vlad  8   9 , Patriciu Achimas-Cadariu  8   9 , Mariela Vasileva-Slaveva  10   11
Affiliations

Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management

Angel Yordanov et al. Cancer Manag Res. .

Abstract

Introduction: Historically, the incidence rate of cervical cancer (CC) in Eastern Europe and particularly in Bulgaria has constantly been higher than that in the other European countries. Adenosquamous carcinoma (ASC) is a rare histological subtype of CC with incidence rate of less than 6 per 100,000. We aimed to analyze the epidemiology and prognosis of all Bulgarian patients with ASC, registered at the Bulgarian National Cancer Registry (BNCR), and to compare patients' characteristics and outcomes with those of patients, treated at a large specialized institution - the Department of Gynecologic Oncology, University Hospital in Pleven, Bulgaria.

Materials and methods: This is a retrospective study of all cases of ASC, registered at the BNCR for a 10-year period of time. The Kaplan-Meier analysis with Log rank test was used to estimate the significant differences.

Results: The incidence rate of ASC was calculated as 3.2% of all CC registered in BNCR and 4.97% of all stage I patients, treated in our department. The 5-year overall survival (OS) rate of all patients with ASC tumors from the registry was 50.5%. A total of 171 (48.4%) of the patients had T1 tumors and a 5-year OS of 67.1%. Lymph node status was a significant prognostic factor for OS (p=0.001). Thirty-one patients with T1 tumors and ASC histology were treated in our department for the same period of time. Lymph node metastases were found in 10 of them (32.2%). The 5-year observed OS in ASC group was 74.19%.

Conclusion: The histological subtype of cancer of the uterine cervix has an impact on prognosis and should not be simply considered as a descriptive characteristic but a poor prognostic feature and should be an integral part of the decision-making in clinical management of patients.

Keywords: adenosquamous cervical carcinoma; clinical features; incidence rate; prognosis; survival rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests in this work.

Figures

Figure 1
Figure 1
Distribution of patients, according to the year of diagnosis and the prevalence of patients with ASC.
Figure 2
Figure 2
Overall survival according to stage, histologic type and lymph nodes status of all T1 patients registered at the Bulgarian National Cancer Registry for the study period.
Figure 3
Figure 3
Comparison of patients, treated at UMHAT “D-r Georgi Stranski” Pleven with all other patients treated in Bulgaria for the study period by age (A), tumor grade (B) and lymph node involvement (C).
See this image and copyright information in PMC

References

    1. CONCORD Working Group; Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3. - DOI - PMC - PubMed
    1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. doi:10.1016/S2214-109X(19)30482-6 - DOI - PMC - PubMed
    1. Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine. 2013;31(Suppl 7):H32–H45. doi:10.1016/j.vaccine.2013.02.071 - DOI - PubMed
    1. International Agency for Reseach on Cancer. Cancer Today. Available from: https://gco.iarc.fr/today/data/factsheets/populations/100-bulgaria-fact-.... Accessed August01, 2020.
    1. Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5(4):e223–e234. doi:10.1016/S2468-2667(20)30010-4 - DOI - PubMed